Is CapsoVision going out of business?

CapsoVision, Inc (CV) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

CapsoVision, Inc (CV) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 2088.65% (YoY)

Five questions, kept separate

Survival - Fragile

Runway cannot be estimated from the available cash and cash-flow fields. Adjusted shares outstanding increased 2088.7% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

7.6% burn burden support a reasonable pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 2088.65% (YoY)
• FCF margin: -169.35%
• Debt / Equity: 0.05x
• Return on Assets: -136.33%
• Revenue growth YoY: 9.89% (YoY)
• Cash Burn Deceleration: -81.97% QoQ improvement (Worsening)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -355.7%
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-08-22.